Simplex Trading’s Apogee Therapeutics APGE Stock Holding History

Simplex Trading’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.55M	Buy	77,808 +15,009	+24%	+$1.09M	﹤0.01%	925
2025 Q4	$4.74M	Buy	+62,799	New	+$3.96M	﹤0.01%	1313
2025 Q1	–	Sell	-73	Closed	-$2.82K	–	8450
2024 Q4	$3K	Buy	73 +35	+92%	+$1.78K	﹤0.01%	7820
2024 Q3	$2K	Buy	+38	New	+$1.82K	﹤0.01%	7940

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Simplex Trading's APGE Position: Q1 2026 in Review

Simplex Trading increased its Apogee Therapeutics (APGE) stake by 24% in Q1 2026, buying an estimated $1.09M and bringing the position to 77,808 shares worth $6.55M. The position accounts for ﹤0.01% of the portfolio, ranked #925.

Simplex Trading first reported a position in APGE in Q3 2024 and has held it in 4 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

Simplex Trading held 77,808 shares of Apogee Therapeutics worth $6.55M as of Q1 2026.
Simplex Trading bought 15,009 Apogee Therapeutics shares in Q1 2026, an estimated $1.09M.
Apogee Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #925 holding.
Simplex Trading first reported a position in Apogee Therapeutics in Q3 2024 and has held it in 4 quarters since.
224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.